For example, the discovery that effective treatment of BRAF-mutated colorectal cancers requires inhibition of both BRAF and EGFR (Prahallad et al, 2012) has resulted in several combination trials (Bernards, 2014). This evidence concerns the gene BRAF and colorectal cancer.